by MM360 Staff | May 23, 2025 | Featured News, Myeloma News
Regeneron Pharmaceuticals has announced promising initial results from its Phase 1b LINKER-MM2 trial, evaluating linvoseltamab in combination with proteasome inhibitors carfilzomib or bortezomib for patients with relapsed/refractory multiple myeloma (R/R MM). These...
by MM360 Staff | May 23, 2025 | Featured News, Myeloma News
The U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee (ODAC) has voted 6-2 in favor of the benefit-risk profile of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) as a monotherapy for adults with high-risk smoldering multiple myeloma...
by MM360 Staff | Jul 7, 2021 | Featured News
Here are the top journal articles from the week of June 24, 2021 as selected by the MYELOMA360 staff. First-line Daratumumab in Addition to Chemotherapy for Newly Diagnosed Multiple Myeloma Patients Who are Transplant Ineligible: A Cost-Effectiveness...
by MM360 Staff | Jun 10, 2021 | Featured News, Myeloma News
Several drugs and drug combinations are used to treat myeloma. The drugs have varying side effects, work differently and are given in different ways. This complexity can make it challenging for patients to decide which treatment option is right for them. As a result,...
by MM360 Staff | Jun 10, 2021 | Featured News, Myeloma News
The post NICE issues draft ‘no’ on first quadruplet combination for England and Wales appeared first on Myeloma UK.
by MM360 Staff | Jun 10, 2021 | Featured News, Myeloma News
The Blood Cancer UK Vaccine Research Collaborative has announced funding for nine research projects, worth £800K in total, that will look at covid vaccine effectiveness in people with blood cancer. Early data suggests that the coronavirus vaccines may not work as well...
